Tyra Biosciences (NASDAQ:TYRA) Stock Rating Lowered by Wall Street Zen

Tyra Biosciences (NASDAQ:TYRA) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

Several other equities research analysts also recently issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tyra Biosciences in a research note on Wednesday, October 8th. Oppenheimer restated an “outperform” rating and set a $36.00 target price on shares of Tyra Biosciences in a report on Wednesday, September 10th. Wedbush upped their price target on shares of Tyra Biosciences from $30.00 to $37.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 16th. Finally, Raymond James Financial initiated coverage on Tyra Biosciences in a research report on Tuesday, September 2nd. They issued a “strong-buy” rating and a $35.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $33.17.

Tyra Biosciences Price Performance

Shares of NASDAQ:TYRA opened at $25.96 on Friday. The business has a 50-day moving average of $19.30 and a two-hundred day moving average of $14.21. The firm has a market capitalization of $1.39 billion, a PE ratio of -13.88 and a beta of 1.09. Tyra Biosciences has a 12 month low of $6.42 and a 12 month high of $26.34.

Tyra Biosciences (NASDAQ:TYRA) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.50) earnings per share for the quarter, meeting the consensus estimate of ($0.50). As a group, research analysts anticipate that Tyra Biosciences will post -1.57 earnings per share for the current year.

Insider Transactions at Tyra Biosciences

In other Tyra Biosciences news, Director Robert J. More sold 10,000 shares of the business’s stock in a transaction on Friday, December 19th. The shares were sold at an average price of $25.00, for a total value of $250,000.00. Following the transaction, the director owned 3,823,425 shares in the company, valued at $95,585,625. The trade was a 0.26% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 15.20% of the stock is owned by company insiders.

Institutional Trading of Tyra Biosciences

A number of hedge funds and other institutional investors have recently modified their holdings of TYRA. HighVista Strategies LLC boosted its holdings in Tyra Biosciences by 4.3% in the second quarter. HighVista Strategies LLC now owns 24,962 shares of the company’s stock valued at $239,000 after purchasing an additional 1,021 shares during the last quarter. American Century Companies Inc. increased its holdings in Tyra Biosciences by 5.8% during the 1st quarter. American Century Companies Inc. now owns 23,431 shares of the company’s stock worth $218,000 after purchasing an additional 1,289 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Tyra Biosciences by 14.5% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 13,182 shares of the company’s stock valued at $126,000 after purchasing an additional 1,668 shares in the last quarter. Federated Hermes Inc. boosted its stake in shares of Tyra Biosciences by 586.3% during the 3rd quarter. Federated Hermes Inc. now owns 2,155 shares of the company’s stock valued at $30,000 after buying an additional 1,841 shares during the last quarter. Finally, Rhumbline Advisers grew its position in shares of Tyra Biosciences by 7.2% during the first quarter. Rhumbline Advisers now owns 28,081 shares of the company’s stock worth $261,000 after buying an additional 1,879 shares in the last quarter. 84.14% of the stock is owned by hedge funds and other institutional investors.

About Tyra Biosciences

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.